4.15

5.87% 0.23

After Hours: 4.14 -0.01 -0.24%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $4.15, with a volume of 3.42M. It is up +5.87% in the last 24 hours and up +28.88% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$3.92

Open:

$3.95

24h Volume:

3.42M

Relative Volume:

1.25

Market Cap:

$458.85M

Revenue:

$34.86M

Net Income/Loss:

$-103.80M

P/E Ratio:

-3.5039

EPS:

-1.1844

Net Cash Flow:

$-96.02M

1W Performance:

+7.24%

1M Performance:

+28.88%

6M Performance:

+106.47%

1Y Performance:

+188.19%

1-Day Range:

$3.855

$4.18

1-Week Range:

$3.605

$4.245

52-Week Range:

$1.36

$4.5981

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	4.15	458.85M	34.86M	-103.80M	-96.02M	-1.1844
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

04:05 AM

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

04:05 AM

05:15 AM

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

05:15 AM

Jun 18, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jun 18, 2026

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance

Jun 18, 2026

C4 Therapeutics, Inc Educational KOL Webinar Transcript - GuruFocus

Jun 18, 2026